Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev
02:59pm, Thursday, 14'th Apr 2022 Zacks Investment Research
The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
Anthem (ANTM) to Post Q1 Earnings: What's in the Offing?
02:38pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Anthem's (ANTM) first-quarter results are likely to benefit from the growing premiums and an uptick in Medicare and Medicaid membership, partly offset by higher expenses.
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
10 High-Yield Retirement Blue-Chip Bargains You Won't Want To Miss
05:22am, Thursday, 14'th Apr 2022 Seeking Alpha
Generating sufficient retirement income that grows faster than inflation is actually not as hard, IF you harness the power of the world's best high-yield blue-chips.
2 Unbelievable Clues That Biotech Revenue May Soon Rival Big Pharma
11:00am, Wednesday, 13'th Apr 2022 The Motley Fool
Biotech today makes us think of blockbuster products.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
06:57pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
03:20pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Merck (MRK) Stock Moves -1.2%: What You Should Know
09:45pm, Monday, 11'th Apr 2022 Zacks Investment Research
Merck (MRK) closed the most recent trading day at $86.63, moving -1.2% from the previous trading session.
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
07:17pm, Friday, 08'th Apr 2022 Zacks Investment Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later
As COVID-19 cases decline in the U.S., White House officials face outbreak
07:09pm, Friday, 08'th Apr 2022 MarketWatch
House Speaker Nancy Pelosi (D-Calif.) is the latest official to test positive for COVID-19 after attending an event with President Joe Biden.
3 Things About Pfizer That Smart Investors Know
03:07pm, Friday, 08'th Apr 2022 The Motley Fool
The next few years might get a little bumpy.
Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY
01:28pm, Friday, 08'th Apr 2022 Zacks Investment Research
Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.
Here's Why a Drop in Moderna's Revenue Wouldn't Be Catastrophic
12:00pm, Friday, 08'th Apr 2022 The Motley Fool
Moderna is preparing the terrain for more sales down the road.
The Zacks Analyst Blog Highlights Merck, CVS Health, American Tower, QUALCOMM and Analog Devices
02:38pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Merck, CVS Health, American Tower, QUALCOMM and Analog Devices are part of top Analyst article.
BA.2 subvariant of omicron accounted for almost 94% of global cases in latest week, the latest sign of how dominant it has become
11:57am, Thursday, 07'th Apr 2022 MarketWatch
The omicron variant of the coronavirus that causes COVID-19 accounted for 99.8% of global new cases in the latest week, the World Health Organization said Wednesday, and the BA.2 subvariant accounted
